Open Label Phase I Trial in Healthy Chinese Male and Female Volunteers to Investigate Pharmacokinetics and Pharmacodynamics of Idarucizumab to Reverse Dabigatran Anticoagulant Activity
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Idarucizumab (Primary) ; Dabigatran etexilate
- Indications Blood coagulation disorders
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 20 Sep 2017 Status changed from active, no longer recruiting to completed.
- 12 Sep 2017 Planned End Date changed from 1 Sep 2017 to 14 Sep 2017.
- 12 Sep 2017 Planned primary completion date changed from 20 Aug 2017 to 14 Sep 2017.